Current Edition

Europe

Aminex Therapeutics Initiates First Clinical Trial of Novel Immunotherapy AMXT 1501 + DFMO in Cancer Patients

Polyamine depletion therapy represents a unique cancer immunotherapy approach Aminex Therapeutics, Inc., a clinical-stage drug development company focused on advanc...
Continue Reading →